NEW YORK (GenomeWeb News) – Allegro Diagnostics has won up to $2.8 million in funding from the National Cancer Institute for clinical studies of its BronchoGen, a molecular diagnostic test for early-stage lung cancer.

The company said today that it will use the Phase I and II Fast Track Small Business Innovation Research funding for a study that will enroll up to 800 patients in 12 sites in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.